NCCN publishes patient resource on genetic testing to guide patient decisionmaking

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Nadeem R. Abu-RustumLouis Burt NaborsMichael J. StylerJames ThompsonErin HeslerNadeem R. Abu-Rustum, Louis Burt Nabors, Michael J. Styler, and James Thompson were recognized by the National Comprehensive Cancer Network as its 2025 awardees who “go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.”

May 30, 2025

Vol.51 No.21

Trials & Tribulations

Genetic counseling can improve genetic screening and accelerate clinical trial success

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

World Cancer Day 2025: A symbol of personal and collective uncertainty

My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable. It’s simply in my DNA.

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

The U.S. Food and Drug Administration and the U.S. Department of Health and Human Services Office of Human Research Protections issued Draft Guidance on the inclusion of tissue biopsies in clinical trials.

January 17, 2025

Vol.51 No.02

By Laura A. Levit, Mark J. Ratain, Julie R. Gralow, Clifford A. Hudis and Elizabeth Garrett-Mayer

Clinical Roundup

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.

January 17, 2025

Vol.51 No.02

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

YOU MAY BE INTERESTED IN

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Genetic counseling can improve genetic screening and accelerate clinical trial success

World Cancer Day 2025: A symbol of personal and collective uncertainty

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

Renew today!

Subscriber content

Never miss an issue!

Login